Relugolix

Relugolix Struktur
737789-87-6
CAS-Nr.
737789-87-6
Englisch Name:
Relugolix
Synonyma:
Relugolix;Altropane;Relugoli;Relugolix TAK-385;1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-6-thieno[4,5-e]pyrimidinyl]phenyl]-3-methoxyurea;RVT-601;TAK-385;CS-2851;ruiugoli;Rui Lugoli
CBNumber:
CB42658205
Summenformel:
C29H27F2N7O5S
Molgewicht:
623.63
MOL-Datei:
737789-87-6.mol

Relugolix Eigenschaften

Schmelzpunkt:
228 °C (decomp)(Solv: ethyl acetate (141-78-6); tetrahydrofuran (109-99-9))
Dichte
1.442±0.06 g/cm3(Predicted)
storage temp. 
Store at -20°C
Löslichkeit
DMSO:20.0(Max Conc. mg/mL);32.1(Max Conc. mM)
Ethanol:1.0(Max Conc. mg/mL);1.6(Max Conc. mM)
Aggregatzustand
A crystalline solid
pka
13.17±0.70(Predicted)
Farbe
White to off-white
InChIKey
AOMXMOCNKJTRQP-UHFFFAOYSA-N
SMILES
N(C1=CC=C(C2SC3=C(C=2CN(C)C)C(=O)N(C2=NN=C(OC)C=C2)C(=O)N3CC2=C(F)C=CC=C2F)C=C1)C(NOC)=O
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H361 Kann vermutlich die Fruchtbarkeit beeinträchtigen oder das Kind im Mutterleib schädigen. Reproduktionstoxizität Kategorie 2 Warnung P201, P202, P281, P308+P313, P405,P501
H371 Kann die Organe schädigen. Spezifische Zielorgan-Toxizität Kategorie 2 Warnung P260, P264, P270, P309+P311, P405,P501
Sicherheit
P201 Vor Gebrauch besondere Anweisungen einholen.
P202 Vor Gebrauch alle Sicherheitshinweise lesen und verstehen.
P260 Dampf/Aerosol/Nebel nicht einatmen.
P264 Nach Gebrauch gründlich waschen.
P264 Nach Gebrauch gründlich waschen.
P270 Bei Gebrauch nicht essen, trinken oder rauchen.
P281 Vorgeschriebene persönliche Schutzausrüstung verwenden.
P308+P313 BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.
P309+P311 BEI Exposition oder Unwohlsein: GIFTINFORMATIONSZENTRUM oder Arzt anrufen.
P405 Unter Verschluss aufbewahren.
P501 Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Relugolix Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. It possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209). Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al.

Verwenden

Relugolix is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment

Clinical Use

Relugolix was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer. Relugolix has also been studied in the symptomatic treatment of endometriosis. 

Nebenwirkungen

Common side effects of Relugolix include: hot flashes; flushing of the skin; sweating; weight gain or loss of ability; pain in the muscles, back, joints or bones; fatigue; diarrhoea; constipation; difficulty sleeping; depression; and breast enlargement. More serious side effects include: dizziness; fainting; rapid heartbeat; or chest pain; swelling of the face, lips, mouth or tongue; difficulty breathing or swallowing; rash; measles; redness of the skin; chest pain or tightness in the chest; or pain in the arms, back, neck or jaw; sudden numbness or weakness of the face, arms, or legs (especially on one side of the body); sudden blurred consciousness; difficulty speaking or understanding; sudden difficulty seeing with one or both eyes; or sudden difficulty walking, walking, or seeing with one or both eyes. or sudden difficulty walking, dizziness, loss of balance or coordination, etc.

Synthese

Relugolix is produced by the reaction of 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione and phenyl N-methoxycarbamate.Relugolix

Relugolix Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Relugolix Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 302)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Shandong Risen-Sun Pharmaceutical Co., Ltd
+86-15552509998 +86-15621883869
liutf@jewim.com.cn China 251 58
Wuhan Topule Biopharmaceutical Co., Ltd
+8618327326525
masar@topule.com China 8467 58
Biopole Pharmatech Co., Ltd.
+8615151475053
biopole@163.com China 37 58
Dorne Chemical Technology co. LTD
+86-86-13583358881 +8618560316533
Ethan@dornechem.com China 3096 58
Beijing Hope Pharmaceutical Co., Ltd.
+86-010-67886402 +8613611125266
market@hopelife.cn China 72 58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
+86-18600796368 +86-18600796368
sales@sjar-tech.com China 474 58
Hebei Weibang Biotechnology Co., Ltd
+8615531157085
abby@weibangbio.com China 8807 58
Hebei Mojin Biotechnology Co., Ltd
+86 13288715578 +8613288715578
sales@hbmojin.com China 12834 58
XuZhou Magic Biotechnology Co., Ltd.
+undefined13921770081
SVP01@magicbiotech.cn China 92 58
shandong perfect biotechnology co.ltd
+86-53169958659 +86-13153181156
sales@sdperfect.com China 294 58

  • TAK-385
  • TKA-385 Relugolix
  • TAK-385,Relugolix
  • CS-2851
  • TAK-385;TAK 385;TAK385
  • 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
  • 10G,100G,500G,1KG
  • N-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy urea
  • 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydro thieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxy urea, Relugolix
  • Relugolix Impurity 17
  • RVT-601
  • Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy-
  • Rui Lugoli
  • Cefepime hydrochloride anhydrous
  • Relugolix
  • Altropane
  • 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-6-thieno[4,5-e]pyrimidinyl]phenyl]-3-methoxyurea
  • Relugolix TAK-385
  • Relugoli
  • N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenylcarbamoyl)-N-methoxybutyramide
  • A60%,B 40%
  • ethyl 5-(4-aminophenyl)-2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)thiophene-3-carboxylate
  • Rui Lu Geli
  • ruiugoli
  • 2H6]-RVT-601
  • RVT-601|||TAK-385
  • Relugolix(NEC-1)
  • 737789-87-6
  • C29H27F2N7O5S
  • API
  • 737789-87-6
Copyright 2019 © ChemicalBook. All rights reserved